Placebo + Romiplostim
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MDS
Conditions
MDS, Myelodysplastic Syndromes, Thrombocytopenia
Trial Timeline
Jul 21, 2008 → Nov 30, 2015
NCT ID
NCT00614523About Placebo + Romiplostim
Placebo + Romiplostim is a phase 2 stage product being developed by Amgen for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT00614523. Target conditions include MDS, Myelodysplastic Syndromes, Thrombocytopenia.
What happened to similar drugs?
0 of 5 similar drugs in MDS were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00614523 | Phase 2 | Completed |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 32 |
| KRN321 | Kyowa Kirin | Phase 2 | 35 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 29 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 44 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 36 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 21 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 29 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 27 |
| Panobinostat | Novartis | Phase 2 | 27 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 27 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 28 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 29 |
| Panobinostat | Novartis | Phase 1 | 29 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 27 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 27 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 40 |
| Darbepoetin Alfa | Amgen | Phase 3 | 40 |